Practising Responsibility · Embracing Mission
STD China National Standard Pharmaceutical Group has long been committed to the reference-material industry and treats social responsibility as the core driver of corporate development. From industry-standard formulation to knowledge sharing, from scientific breakthroughs that safeguard livelihoods to philanthropic reinvestment in research — we live by the principles of "Integrity, Pragmatism, Diligence and Accountability" to fulfil the mission of a Chinese standards enterprise.
A company's value is reflected not only in how it serves its customers but also in how it honours its duties tothe country, society and employees
"Standards determine quality. What standards you have determines what quality you have — only high standards deliver high quality."
— President Xi Jinping
Donated to the Chinese Natural Science Foundation to advance national-standard research
Planned investment in scientific philanthropy over the next decade
National / provincial-level research projects undertaken
Countries & regions with deep collaboration on Chinese standards
Our industry is one where "a small weight bears a thousand pounds". The precision of reference materials directly defines the safety baseline for the daily lives of millions of households. New drug development, vaccine safety, infant-formula testing — and even the air we breathe and the water we drink — are all judged by an invisible "ruler", that is, reference materials. The accuracy of this ruler is directly tied to the safety baseline of the national economy and the quality of life.
As an enterprise that lives out the country's strategic development plan, STD has always kept pace with national standards-deployment initiatives. We follow the Metrology Law, the Outline for the Development of Standardisation, and the 15th Five-Year Plan as our action guidelines, integrating Party building into the full chain of R&D and production, and turning Party-member先锋 posts into先锋 of攻坚. With the 2026 implementation of the Pharmaceutical Administration Law Implementation Regulations and the upcoming end-of-year Standard Material Management Measures, STD consistently stays ahead of regulatory requirements.
What drives STD forward is not merely becoming a successful company, but becoming a globally trusted "reference-material library" in the minds of scientists worldwide. We aspire for chemical standards led by Chinese scientists to become the common rule of every laboratory on the planet — and the foundation of all this is our accountability to country, society and employees.
Integrity
Earn global trust with truthful data and reliable products. Every milligram of reference material carries the weight of national-economy quality and safety.
Pragmatism
No shortcuts, no empty slogans. From raw-material intake to shipment, more than 20 critical control points ensure compliance and full traceability.
Diligence
Over a decade of积累 building the three-library data platform, 58+ national invention patents and 93 intellectual-property rights — the patience of "ten years to sharpen a sword" builds industry cornerstones.
Accountability
From the soft-penicilic-acid emergency breakthrough to publishing the impurity compilation, from the RMB 10M foundation donation to the RMB 100M scientific-philanthropy plan — we interpret responsibility through action.
Scientific PhilanthropyDoing Business Boldly · Doing Good Quietly
For years we have followed the principle of "doing business boldly, doing good quietly", contributing our part to the development of science and people's livelihood.
We firmly believe that the value of a reference-material enterprise extends beyond commercial success — it must give back to society through tangible actions and advance scientific progress. Foundation philanthropy is our public practice of mission responsibility.
Chinese Natural Science Foundation · Honorary Chair Unit
Honoured in 2025 · RMB 10M donation
In 2025, STD China National Standard Pharmaceutical Group was honoured as an Honorary Chair Unit of the Chinese Natural Science Foundation, and entered a strategic partnership with The Chinese University of Hong Kong, Shenzhen, donating RMB 10 million to support national-standard research. The Foundation is a non-profit charity dedicated to supporting Chinese scholars. As an Honorary Chair Unit, STD stands alongside renowned institutions such as the Shaw Foundation and the Li Ka Shing Foundation to advance Chinese scientific research. This is not a simple donation but a long-term commitment that deeply integrates our technical strengths with our philanthropic mission.
STD's scientific philanthropy aligns closely with our core business: we focus on funding research in pharmaceutical science and reference materials, and leverage our technical expertise in reference-standard R&D, analytical testing and impurity research to provide professional support to funded projects — so that philanthropy is not only financial support but also capability empowerment.
For years we have followed the principle of "doing business boldly, doing good quietly", contributing our part to science and livelihood. Over the next decade we plan to invest RMB 100 million in scientific philanthropy, hoping to help more people.
Beyond the foundation donation, STD's scientific philanthropy spans many layers: compiling a decade of industry insights into a book distributed without profit, building the three-library big-data platform to share knowledge with the industry, and investing without counting cost in research breakthroughs during public-health events — all are concrete embodiments of "doing business boldly, doing good quietly".
Knowledge SharingA Decade of Accumulation Empowering the Industry
Compiling years of data into a book and building an industry-grade big-data platform — not for profit, but as our mission to advance the industry.
"Compendium of Related Substances for Pharmaceutical R&D and Quality Control" — the industry's "impurity dictionary"
Over more than a decade, STD has compiled its three-library data and experience into this compendium. Upon completion, the book was strongly recommended and supported by the Chinese Pharmacopoeia Commission and published by China Health Media Group — the authoritative information publisher under the National Medical Products Administration — as a supplementary volume to the 2025 edition of the Chinese Pharmacopoeia.
The book is widely known as the industry's "impurity dictionary", systematically cataloguing more than 3,000 critical substances and helping R&D staff shorten development cycles by 15–20%. From compilation to distribution, it has always been non-profit. Today the Chinese Pharmacopoeia Commission, China Health Media Group and multiple CAS academicians continue to recommend the book across many scenarios.
Three-Library Big-Data Platform — industry-grade data sharing
Even more powerful than physical samples are globally shareable data resources. We have built the industry's only "Reference-Material Big-Data Platform", consisting of three core databases:
The three libraries' significance lies in this: no matter what the customer needs, we can leverage powerful data support to find the right solution in the shortest time. This data resource is not only STD's business moat but also the knowledge infrastructure we return to the industry.
Scientific BreakthroughsTurning High Risk into Deliverables
Rapid response in public-health events — protecting livelihoods with technical reserves and R&D capability, fulfilling the social responsibility of a standards enterprise.
Modern drug development places increasing focus on high-risk, scarce or extremely unstable molecular impurities. STD has long focused on the research of extremely unstable, structurally complex or high-value molecules, and through systematic R&D and technical accumulation converts high-risk scientific challenges into controllable, deliverable solutions.
Soft Penicillic Acid — emergency breakthrough for the Japanese Kobayashi Pharmaceutical incident
In 2024, the toxic substance soft penicillic acid produced by Penicillium mould was detected in Japanese Kobayashi Pharmaceutical health products, with 119 deaths recorded before disclosure. After obtaining relevant information, STD quickly organised a team for R&D and, relying on the three-library system, secured reference samples within just over a month and ramped up volume production.
STD became the first domestic premium supplier of this compound, providing critical reference-material support for global drug-safety regulation.
Nitrosamine Impurities — systematic coverage of 4,000 APIs
Since N-nitrosodimethylamine genotoxic impurity was detected in valsartan API in 2018, nitrosamine impurities have become a mandatory research item for drug-registration supplements. STD has been incrementally developing N-nitrosamine impurities across 4,000 APIs, with about 500 compounds becoming long-term designated supply units for the NIFDC.
In July 2025, STD achieved a major breakthrough in the synthesis of nitroso derivatives of dihydropyridine calcium-channel blockers — published as a cover article in the international top journal OPR&D — with significant implications for drug safety, cost optimisation and the reference-material system.
Intellectual Property & Research Outcomes
All of these achievements stem from a core R&D team of more than 100 people, with master's and PhD degrees accounting for 35%. Over the years, the Central China R&D Centre has invested more than RMB 100 million in R&D, with annual R&D investment growing at 20%.
National invention patents
Total intellectual-property rights
National/provincial research projects
Journal papers published
STD ranks first in intellectual-property quantity within China's reference-material industry and has undertaken 22 national/provincial research projects. We know that only the best technology sustains the strongest market competitiveness — and that technical strength is the backbone of our social responsibility.
Chinese Standards Going GlobalEmpowering the World's Standards
Deeply integrated into the Belt-and-Road Initiative, representing Chinese standards enterprises on the global stage and contributing to worldwide pharmaceutical research.
As a leading enterprise in the standards industry, STD deeply integrates into the national Belt-and-Road Initiative and represents Chinese standards enterprises in following government overseas missions and participating in China-Africa and China-Europe cooperation. At the China-Africa Forum we presented our own suggestions on the development of global standards.
Many overseas customers regard STD as a French-standard brand from China. It is with this mission that we help advance world standards. To date we have reached cooperation with more than 100 countries and regions worldwide, with deep cooperation in over 40.
Countries & regions in cooperation
Deep-cooperation countries
Pharma enterprises & top research institutions served
Continents covered by our supply system
Our supply-chain network is deeply embedded in China's pharmaceutical-industrial core, with long-term strategic partnerships established with leading enterprises such as China Resources Pharmaceutical, Humanwell Healthcare, Qilu Pharmaceutical and Hengrui Medicine. Globally we maintain stable ties with Pfizer (US), KRKA (Slovenia), DEVA Holding (Turkey), Europharm (Brazil) and Promomed (Russia).
Beyond commercial pharma partners, we are a designated cooperation unit for the National Medical Products Administration and the Ministry of Public Security Anti-Drug Lab — credentials that not only certify the completeness of our product documentation but also verify the safety and reliability of our supply chain for controlled substances.
STD's national recognition comes not only from commercial customers but also from the care of governments at all levels. Leaders and experts from the NMPA, the Ministry of Public Security Anti-Drug Lab, the NIM and other institutions are not only STD's long-term partners but also key witnesses to the professionalism and credibility of China National Standard Pharmaceutical Group.
Looking forward to partnering with like-minded alliesto bring Chinese standards to the world
STD China National Standard Pharmaceutical Group · Safeguarding Quality with Standards · Giving Back to Society with Accountability
Learn about scientific-philanthropy cooperation